Detail akcie Guerbet SA online

Business Summary: Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Guerbet SA revenues decreased 7% to EUR387.8M. Net income applicable to common stockholders decreased 76% to EUR2.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Other financial income and expenses increase from EUR926K to EUR2.2M (expense), Net allocations to provisions increase from EUR575K to EUR1.7M (expense).